Preemptive care can improve overall healthcare outcomes and reduce costs for patients with congestive heart failure (CHF). Nearly 6 million people in the U.S. have heart failure and it’s the most common reason for hospitalization for people age 65 and older, according to the Cleveland Clinic. Timely detection of changes in key health signs can help CHF patients get the treatment they need and avoid rehospitalization. Donisi Health announced a study that reported the accuracy of the company’s infrared optical-based contact-free biosensor to detect pulmonary congestion in congestive heart failure (CHF) patients.
The Gili Pro BioSensor is a contact-free tabletop device that detects pulmonary congestion. The Gili Pro senses nano-vibrations of a patient’s chest with an infrared optical sensor. The Gili system uses AI and proprietary algorithms to analyze the vibration data. In the reported study, which Donisi submitted for publication, testers examined 227 CHF patients with the device. The test group included 101 patients with pulmonary congestion and 126 patients with no congestion. Two cardiologists verified the analysis of the 101 patients with pulmonary congestion. The test results showed the Gili system had a 91% accuracy rate in detecting pulmonary congestion for both test sensitivity (true positives) and specificity (true negatives).
The FDA cleared Donisi’s Gili Pro Biosensor for remotely detecting heart rate and respiratory rate simultaneously, according to a Donisi news release. Donisi plans to submit the latest study results to the FDA for clearance to use the Gili to detect pulmonary congestion in home settings.
Advances in clinical-grade home testing continue to support the case for remote patient monitoring. In addition to the comfort and convenience of home testing and, in this case, the potential to decrease rehospitalization, such devices and platforms also support aging-at-home.
